Please assess the completion status of the following clinical trial:

Trial Title: Use of Rituximab in Opsoclonus-Myoclonus in Children With Neuroblastoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Pathologic confirmation of diagnosis of neuroblastoma Surgical resection of primary tumor Symptoms of OMS despite a minimum of one month of steroid therapy Must meet all laboratory criteria to demonstrate adequate organ function -~Exclusion Criteria:~Patients currently receiving systemic chemotherapy for treatment of neuroblastoma Patients with documented active infection Patients who are HIV, Hep B or Hep C positive Organ toxicity from any prior therapy or surgical intervention must be resolved prior to study entry~-

- Gender: ALL
- Minimum Age: 2 Months
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Rituximab (Type: OTHER): Single Arm

Based on this trial design, predict the completion outcome and termination type (if applicable).